47 results about "Hepatitis B virus core" patented technology

A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.

A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.

The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

The invention discloses fusion protein of divisive ranilla luciferase and HBC (hepatitis B core). The fusion protein is obtained by joint connection of 1 to 229 amino acids of the N-terminal of the ranilla luciferase and core protein of hepatitis B virus (HBV), or obtained by joint connection of 229 to 311 amino acids of the N-terminal of the ranilla luciferase and the core protein of the HBV, the sequence of the amino acids is as shown in SEQ (sequence) ID (identity) No: 1 and No: 3 respectively, and nucleotide sequence encoding the two fusion protein is as shown in SEQ ID No: 2 and No: 4 respectively. The invention further discloses a carrier containing the nucleotide sequence as is shown in the SEQ ID No: 2 and No: 4. and discloses an application about whether the fusion protein as is shown in the SEQ ID No: 1 or the No: 3 is formed or not in indication of core protein dimers of the HBV. An importation foundation is laid for establishing cell models for drug screening in formation of the anti-HBC dimers.

The invention discloses a recombinant human hepatitis B virus core protein fused protein. The fused protein comprises a protein (X), a linker peptide (L) and a hepatitis B virus core protein (HBc) from the end N to the end C in sequence; the linker peptide (L) has the amino acid sequence of Gly-Ser-(Gly-Gly-Gly-Gly-Ser)n, and n is an integer between 2 and 20 and is 9 or 18, particularly; the end C of the linker peptide (L) is connected with the end N of the hepatitis B virus core protein (HBc); the end C of the protein (X) is connected with the end N of the linker peptide (L); and the protein (X) is a red fluorescent protein or vesicular stomatitis virus G glycoprotein. The hepatitis B virus core protein (HBc) is connected with the functional protein, and the functions of the proteins on two ends of the linker peptide (L) can be both guranteed. The problem in the prior art that the functions of the hepatitis B virus core protein (HBc) and the functions of the functional protein can not be both guaranteed after the hepatitis B virus core protein (HBc) is fused with the functional protein is solved. The fused protein is of great importance to the research on the hepatitis B virus (HBV).

The invention discloses HBV pre-c-Fc recombinant protein and a coding nucleotide sequence thereof and discloses a recombinant vector containing a coding sequence of the protein and a host cell. The invention further discloses a recombinant baculovirus, a method of obtaining the recombinant baculovirus, and a method of expressing the HBV pre-c-Fc recombinant protein in an insect baculovirus expression system, and also discloses a recombinant baculovirus containing a HBV pre-c-Fc coding gene and applications of the HBV pre-c-Fc recombinant protein in preparation of vaccines or medicines preventing or treating hepatitis B. After a BALB/c mouse is subjected to injection immunization with the HBV pre-c-Fc recombinant protein, detection shows that the generating amount of a hepatitis B virus core protein antibody in serum of the mouse is far higher than that in a situation that an antigen used for preparing hepatitis B vaccines in traditional methods is used.

The invention relates to a hepatitis B virus multi-epitope fusion protein and a preparation method and application thereof. The fusion protein is obtained by inserting hepatitis B virus multi-epitope fusion peptide (with the sequence shown as SEQIDNo.1) formed by serially connecting HBsAg313-321, HBsAg335-343, Pol150-159, Pol455-463 and Padre epitopes through connecting peptide between amino acidat the 78th position and amino acid at the 79th position of a hepatitis B virus core protein; and the preparation method comprises the following steps of: constructing a hepatitis B virus multi-epitope fusion protein expression plasmid pET28-HBc-HP; performing isopropyl thiogalactoside (IPTG) inducing expression by using an Escherichia coli expression system; and purifying by using affinity chromatography. The fusion protein carries a plurality of supertype epitopes of hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBcAg) and polymerase, is viral particles, has the advantages of strong immunogenicity, wide applicable range and the like, and can be used for preparing therapeutic hepatitis B vaccines.

The invention discloses an immunogen HM4-M2e as well as a preparation method and an application thereof. Hepatitis B virus core protein HM4 is used as carrier protein and crosslinked with designed and synthesized polypeptide M2e through SMCC, and thus the immunogen HM4-M2e is obtained. Experiments prove that a drug prepared from the prepared immunogen HM4-M2e used as an effective ingredient of an influenza vaccine and a proper immunologic adjuvant used as an auxiliary material has a better immune effect. Besides, the used carrier protein is suitable for mass industrial production, the crosslinking rate is high, the preparation time is short, and the production cost is reduced.

The invention discloses an enteroviral chimeric virus-like particle vaccine and a preparation method and application thereof and belongs to the field of biotechnologies. Chimeric virus-like particles are hepatitis b virus core protein based recombinant enteroviral multi-epitope chimeric antigen protein, and the amino acid sequence of the particles is shown as SEQ ID NO.1. The nucleotide sequence of a DNA fragment encoding the virus-like particles is shown as SEQ ID NO.2. The DNA fragment shown as SEQ ID NO.2 is cloned to an escherichia coli expression vector to establish recombinant expression plasmids. The recombinant expression plasmids are converted into escherichia coli to obtain engineering bacteria. The engineering bacteria are cultured, and enteroviral chimeric virus-like particles are obtained through the operations, such as inducing expression and protein purification. The virus-like particles can induce a body to produce specific body fluid and cellular immune response, can be used for immune prevention of enterovirus EV71 and CA16 infection of people and susceptible animals and is used for preparation of the enteroviral vaccine.

The invention provides recombinant protein as well as a preparation method and application thereof. The recombinant protein comprises Tau protein and hepatitis B virus core protein. The recombinant protein adopts Tau294-305 and the hepatitis B virus core protein to perform recombination, T294-HBc for fusion expression is self-assembled into HBc chimeric virus-like particles, with surface displaying Tau294-305, and vaccine is good in homogeneity, simple to prepare, high in immunogenicity and small in side effect, and has a good application prospect in terms of the treatment of dementia, such asalzheimer disease, frontotemporal dementia, corticobasal degeneration, Pick disease and progressive supranuclear palsy, caused by Tau lesion.

A gene engineering vaccine for preventing pig cysticercosis and its preparation process are disclosed. The process includes the steps: making the hepatitis B virus core protein as carrier, inserting cysticercus cellulosae protective antigen gene in multiple locations between the first amino acid to No. 183 amino acid hepatitis B core protein, cloning to procaryon expression plasmid or eucaryon expression plasmid, transforming host bacteria, expressing by inducing aim gene and acquiring aim protein or column purified eucaryon expression plasmid DNA therefore, subunit protein vaccine or nucleic acid vaccine for preventing pig cysticercosis are obtained.

Method for inducing TH1 type immune response by inoculating HBs DNA vaccine through using HBV core protein reinforced gene gun, wherein co-leading/co-expression HBV Core gene is used as adjuvant simultaneously while inoculating plasmid HBs DNA vaccine with a gene gun. The animal immunity experiment shows that, the invention can be applied to reinforce the TH1 type immune response level induced through gene gun vaccinated HBs DNA vaccine, including total IgG, IgG2a, specific CTL activity, and antigen specific IFN-gamma production capacity.

The invention relates to a vector used for displaying antigenic epitope by using hepatitis B virus core particles, an animal vaccine, and a preparation method thereof. According to the invention, a DNA artificial synthesis method is adopted, and a coding DNA sequence of amino acid necessary for hepatitis B virus core protein is synthesized. In the synthesis process, a coding DNA sequence of hepatitis B virus core protein true peptide 1-149 site amino acid is adopted as a framework; 79-82 site amino acid coding sequence in the framework is removed, and only coding DNA relevant to virus particle assembly is preserved; for facilitating the insertion of other antigenic proteins in the hepatitis B virus core particle protein, a segment of DNA sequence coding flexible peptide is specially inserted at a position of the 79-82 site amino acid, and three endonuclease sites are introduced into the sequence, such that gene operation is facilitated; the above synthesized DNA segment is cloned into a gene cloning vector pUC18, such that a special vector pZNVC used for displaying antigenic epitope is formed; a synthesized DNA segment of an antigenic protein gene or coding epitope is inserted into pZNVC, and fusion protein is expressed in prokaryotic organisms or eukaryotic organisms. 78 amino acids on N-end of hepatitis B virus and 68 amino acids on C-end of hepatitis B virus can be folded into two columnar bodies, such that building blocks used for assembling the core protein particle are formed; flexible peptide forms a bond connecting the two columnar bodies; and proteins inserted between the flexible peptide protrude on the surface of the viral particles. The flexible peptide is composed of a series of small amino acids without side chain, and has certain flexibility. The flexible peptide does not affect the hepatitis B virus core particle protein and antigenic protein in independently and respectively folding into natural molecular structures. pZNVC is used for displaying antigenic protein antigenic epitopes, such that the existence state of the antigenic epitopes on natural pathogen outer membrane can be simulated to a maximal extent.

The invention provides vaccine universal vectors HBc-S and HBc (1-183) -S which are constructed based on SpyCatcher/SpyTag and take hepatitis B virus core protein as a basis. SpyCatcher is displayed in a main immunodominance region of VLPs and can be subjected to an adhesion reaction with SpyTag at the amino terminal of epitope polypeptide, linear, annular and phosphorylated B cell epitopes SP aredisplayed on the surfaces of VLPs, and a series of HBc-S-P VLPs vaccines are prepared. Mice immunized with the vaccines can generate antibodies specific to the epitopes; and HBc-S-pTau 422 remarkablyimproves cognition and pathological changes of Alzheimer' S disease transgenic mice; HBc (1-183) -S induces Th1 type immunoreaction, and the HBc (1-183) -S-OVA vaccines are of a VLP structure, can activate and promote maturation of DCs, remarkably inhibit growth of tumors and prolong the lifetime of the tumors.

A pharmaceutical composition for use in killing and/or inhibiting the growth and/or proliferation of a microorganism in a subject in need thereof, or for treating a subject afflicted with a microbial infection is disclosed. The composition comprises: (a) an effective amount of an isolated peptide, wherein the peptide comprises the arginine-rich carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an antimicrobial activity; and (b) a pharmaceutically acceptable carrier. The peptide exhibits an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi.

The present invention relates generally to the field of virology. More particularly, the invention relates to the discovery that peptides, which bind to the Hepatitis B virus (HBV) core and e antigens, can be used to inhibit HBV infection. Embodiments concern “binding partners”, which include peptides, peptidomimetics, and chemicals that resemble these molecules that interact with HBV core and e antigens, biological complexes having HBV core and e antigens joined to said binding partners, methods of identifying such binding partners, pharmaceuticals having binding partners, and methods of treatments and prevention of HBV infection.

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequence of HBV core protein, as well as genetic constructs/vectors and vaccines that express said protein sequences. Also provided herein are methods for generating an immune response against HBV using the nucleic acid sequences that are provided.